Journal: Annual review of virology

Article Title: Challenges of Making Effective Influenza Vaccines

doi: 10.1146/annurev-virology-010320-044746

Figure Lengend Snippet: FDA-approved influenza vaccines for the 2019–2020 season

Article Snippet: While it is clearly important to develop new universal vaccines that elicit broader immunity, we argue that it is equally important to invest in efforts to improve current seasonal influenza vaccines. table ft1 table-wrap mode="anchored" t5 caption a7 Platform Brand name Manufacturer Type Inactivating agent Component(s) Formulation Antigen amount Licensed for (age) Route of admini stration Egg based Fluarix GlaxoSmithKline Inactivated Formaldehyde Split with deoxycholate Quadrivalent 15 ug HA ≥6 months IM FluLaval GlaxoSmithKline Inactivated UV light and formaldehyde Split with deoxycholate Quadrivalent 15 ug HA ≥6 months IM or ID Fluzone Sanofi Pasteur Inactivated Formaldehyde Split with Triton X-100 Quadrivalent 15 ug HA ≥6 months IM Fluzone High Dose Sanofi Pasteur Inactivated Formaldehyde Split with Triton X-100 Trivalent 60 ug HA ≥65 years IM Afluria Seqirus Inactivated BPL Split with sodium taurodeoxy-cholate Quadrivalent 15 ug HA >5 years IM or ID Fluad Seqirus Inactivated Formaldehyde Subunit Trivalent + Adjuvant MF59 15 ug HA ≥65 years IM FluMist AstraZeneca Live attenuated Not applicable Whole purified virus Quadrivalent 10 6.5−7.5 FFU/0.2 mL 2–49 years IN Cell culture based Flucelvax Seqirus Inactivated BPL Subunit Quadrivalent 15 ug HA >4 years IM Recombinant protein Flublok Sanofi Pasteur Protein only Not applicable Subunit Quadrivalent 45 ug HA ≥18 years IM Open in a separate window Abbreviations: BPL, beta-propiolactone; FDA, Food and Drug Administration; FFU, focus-forming units; HA, hemagglutinin; ID, intradermal; IM, intramuscular; IN, intranasal.

Techniques: Purification, Cell Culture, Recombinant